Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

593 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interleukin-9 protects from microglia- and TNF-mediated synaptotoxicity in experimental multiple sclerosis.
Guadalupi L, Vanni V, Balletta S, Caioli S, De Vito F, Fresegna D, Sanna K, Nencini M, Donninelli G, Volpe E, Mariani F, Battistini L, Stampanoni Bassi M, Gilio L, Bruno A, Dolcetti E, Buttari F, Mandolesi G, Centonze D, Musella A. Guadalupi L, et al. Among authors: centonze d. J Neuroinflammation. 2024 May 14;21(1):128. doi: 10.1186/s12974-024-03120-9. J Neuroinflammation. 2024. PMID: 38745307
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab.
Signoriello E, Signori A, Lus G, Romano G, Marfia GA, Landi D, Napoli F, D' Amico E, Zanghí A, Di Filippo PS, Caliendo D, Carotenuto A, Spiezia AL, Fantozzi R, Centonze D, Lucchini M, Mirabella M, Cocco E, Frau J, Maniscalco GT, Di Battista ME, Foschi M, Surcinelli A, Bonavita S, Abbadessa G, Pasquali L, Di Gregorio M, Ferrò MT, Sormani MP, Schiavetti I; ON focus study group. Signoriello E, et al. Among authors: centonze d. Mult Scler Relat Disord. 2024 Apr 6;87:105594. doi: 10.1016/j.msard.2024.105594. Online ahead of print. Mult Scler Relat Disord. 2024. PMID: 38718748 Free article.
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
Zanghì A, Borriello G, Bonavita S, Fantozzi R, Signoriello E, Barone S, Abbadessa G, Cellerino M, Ziccone V, Miele G, Lus G, Valentino P, Bucello S, Inglese M, Centonze D, Avolio C, D'Amico E. Zanghì A, et al. Among authors: centonze d. J Neurol. 2024 May 4. doi: 10.1007/s00415-024-12360-x. Online ahead of print. J Neurol. 2024. PMID: 38704488
Low-contrast visual acuity test is associated with central inflammation and predicts disability development in newly diagnosed multiple sclerosis patients.
Dolcetti E, Buttari F, Bruno A, Azzolini F, Gilio L, Di Caprio V, Lauritano G, Borrelli A, Galifi G, Furlan R, Finardi A, Musella A, Guadalupi L, Mandolesi G, Rovella V, Centonze D, Stampanoni Bassi M. Dolcetti E, et al. Among authors: centonze d. Front Neurol. 2024 Feb 23;15:1326506. doi: 10.3389/fneur.2024.1326506. eCollection 2024. Front Neurol. 2024. PMID: 38585351 Free PMC article.
Pharmacological blockade of 2-AG degradation ameliorates clinical, neuroinflammatory and synaptic alterations in experimental autoimmune encephalomyelitis.
Guadalupi L, Mandolesi G, Vanni V, Balletta S, Caioli S, Pavlovic A, De Vito F, Fresegna D, Sanna K, Vitiello L, Nencini M, Tartacca A, Mariani F, Rovella V, Schippling S, Ruf I, Collin L, Centonze D, Musella A. Guadalupi L, et al. Among authors: centonze d. Neuropharmacology. 2024 Jul 1;252:109940. doi: 10.1016/j.neuropharm.2024.109940. Epub 2024 Apr 2. Neuropharmacology. 2024. PMID: 38570068 Free article.
Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.
Signoriello E, Foschi M, Lanzillo R, Frau J, Cocco E, Borriello G, Ianniello A, Trotta M, Landi D, Maniscalco GT, Ruscica F, Toscano S, Patti F, Zanghì A, D'Amico E, Fantozzi R, Centonze D, Lus G, Bonavita S. Signoriello E, et al. Among authors: centonze d. J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12291-7. Online ahead of print. J Neurol. 2024. PMID: 38568225
Human expressive movements: The boundary between health and disease from a contaminated perspective.
Pascarella A, Gasparini S, Bellia A, Bertolotti E, Bessi B, Cantalupo G, Centonze D, Cianci V, Cornaggia CM, Costabile F, Gambardella A, Labate A, Malacrino C, Magaudda A, Mula M, Paladin F, Pizza G, Tassinari CA, Vermiglio E, Ferlazzo E, Aguglia U. Pascarella A, et al. Among authors: centonze d. Neurosci Biobehav Rev. 2024 Jun;161:105639. doi: 10.1016/j.neubiorev.2024.105639. Epub 2024 Mar 28. Neurosci Biobehav Rev. 2024. PMID: 38552759 Free article. Review. No abstract available.
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop).
Schiavetti I, Signori A, Albanese A, Frau J, Cocco E, Lorefice L, di Lemme S, Fantozzi R, Centonze D, Landi D, Marfia G, Signoriello E, Lus G, Zecca C, Gobbi C, Iodice R, Malimpensa L, Cordioli C, Ferraro D, Ruscica F, Pasquali L, Repice A, Immovilli P, Ferrò MT, Bonavita S, Di Filippo M, Abbadessa G, Govone F, Sormani MP; CladStop study group. Schiavetti I, et al. Among authors: centonze d. Eur J Neurol. 2024 Jun;31(6):e16250. doi: 10.1111/ene.16250. Epub 2024 Mar 28. Eur J Neurol. 2024. PMID: 38549186
593 results